AUAUniversity

AUA2023 Journal of Urology Lecture: Surgery Harms Surgeons. What can we do?

Speaker: Dr. Kevin Turner

AUA2023 Ramon Guiteras Lecture: The Complicated Decisions Required to Eliminate Never Events

Speaker: Dr Louis Kavoussi, Smith Institute For Urology.

AUA2023 John Duckett Memorial Lecture: Innovation by Necessity: Improving Urodynamics for Children with Spina Bifida

Speaker: Dr. Johnathan Routh, Chief of Children's Surgery, Duke University School of Medicine.

AUA2023 John K. Lattimer Lecture: Innovation in Urology: From a Seminal “Why” to a Functional “How”

Speaker: Dr. Ralph Clayman, Distinguished Professor / Endowed Chair in Endourology, University of California, Irvine.

The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer:

Adjuvant Therapies for High-Risk Non-Metastatic Kidney Cancer

CME Available: https://auau.auanet.org/node/39542

Release Date: December, 2023

Expiration Date: December, 2024

LEARNING OBJECTIVES:

At the conclusion of this activity, participants will be able to:

1. Identify the rationale behind using adjuvant therapies in high-risk non-metastatic kidney cancer and the goals of adjuvant treatment.

2. Describe the adjuvant therapies that have been investigated to date for high-risk non-metastatic kidney cancer, including targeted therapies, immunotherapies, and combination approaches.

3. Discuss the challenges and limitations associated with adjuvant therapy trials in high-risk non-metastatic kidney cancer, such as patient selection, trial design, and long-term follow-up.

ACKNOWLEDGEMENTS:

Support provided by independent educational grants from: 

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC 

Lantheus Medical Imaging

Merck & Co., Inc.

The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer:

The Latest Breakthroughs in Immunotherapy for GU Cancers

CME Available: https://auau.auanet.org/node/39543

Release Date: December, 2023

Expiration Date: December, 2024

LEARNING OBJECTIVES:

At the conclusion of this activity, participants will be able to:

1. Identify the newest immunotherapy drugs approved for prostate, bladder, and kidney cancer, including immune checkpoint inhibitors and other novel immunotherapies.

2. Discuss the clinical evidence supporting the use of these immunotherapy drugs in prostate, bladder, and kidney cancer, including data from pivotal clinical trials, response rates, and survival outcomes.

3. Evaluate the safety profile and potential immune-related adverse events associated with the newest immunotherapy drugs in GU cancers.

ACKNOWLEDGEMENTS:

Support provided by independent educational grants from: 

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC 

Lantheus Medical Imaging

Merck & Co., Inc.

The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer:

Germline Testing and Novel Approaches to Targeting Genetic Mutations in Prostate Cancer

CME Available: auau.auanet.org/node/39487

Release Date: December, 2023

Expiration Date: December, 2024

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

1. Identify the indications for germline testing in prostate cancer patients.

2. Explain how germline testing is used to identify genetic mutations in genitourinary (GU) cancers, specifically focusing on prostate cancer.

3. Analyze the potential advantages and challenges associated with using germline testing and targeted therapies in the management of prostate cancer.

ACKNOWLEDGEMENTS:

Support provided by independent educational grants from:

Astellas and Pfizer, Inc

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Lantheus Medical Imaging

Merck & Co., Inc.

The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer:

Novel Imaging for Genitourinary Cancers - Diagnostics and Theranostics

CME Available: https://auau.auanet.org/node/39411

Release Date: December, 2023

Expiration Date: December, 2024

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

1. Review the latest clinical trials investigating the use of PET imaging agents in prostate, kidney, and urothelial cancer, including their diagnostic accuracy and impact on patient management.

2. Discuss the available PET imaging agents for prostate cancer, with a specific focus on PSMA (Prostate-Specific Membrane Antigen) PET imaging, including its mechanism of action and its potential for detection of primary tumors, lymph node metastases, and distant metastases.

3. Discuss the benefits of incorporating PET imaging, including PSMA PET, in guiding treatment decisions for GU cancers, such as its impact on treatment selection, treatment response assessment, and the potential for theranostic approaches.

ACKNOWLEDGEMENTS:

Support provided by independent educational grants from: 

Astellas and Pfizer, Inc

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC 

Lantheus Medical Imaging

Merck & Co., Inc.

The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer:

Early Detection of Prostate Cancer: AUA/SUO Guideline (2023)

CME Available: https://auau.auanet.org/node/39410

Release Date: December, 2023

Expiration Date: December, 2024

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

1. Discuss the potential benefits, limitations, and controversies associated with prostate cancer screening.

2. Summarize the key recommendations provided in the AUA/SUO Guideline regarding early detection strategies for prostate cancer.

3. Analyze the implications of the AUA/SUO Guideline on clinical practice, shared decision-making, and patient counseling regarding early detection of prostate cancer.

ACKNOWLEDGEMENTS:

Support provided by independent educational grants from: 

Astellas and Pfizer

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC 

Lantheus Medical Imaging

Merck & Co., Inc.

The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer:

Treatment Paradigms for Intermediate and High-Risk Non-Muscle Invasive Bladder Cancer

CME Available: https://auau.auanet.org/node/39374

Release Date: December, 2023

Expiration Date: December, 2024

LEARNING OBJECTIVES:

At the conclusion of this activity, participants will be able to:

1. Describe the importance of individualized treatment decision-making and shared decision-making in the management of intermediate and high-risk NMIBC.

2. Discuss the challenges associated with BCG shortage and its impact on patient care and treatment decisions.

3. Evaluate alternative intravesical therapies for NMIBC, such as chemotherapeutic agents (e.g., mitomycin C, gemcitabine), novel immunotherapies (e.g., intravesical pembrolizumab), and clinical trials.

ACKNOWLEDGEMENTS:

Support provided by independent educational grants from: 

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC 

Lantheus Medical Imaging

Merck & Co., Inc.